TGA approved new indication for semaglutide drug in December 2024, but allocation to PBS still to be decided
- Follow our Australia news live blog for latest updates
- Get our breaking news email, free app or daily news podcast
A weight loss drug has been approved to treat heart disease in overweight and obese patients by Australia’s medicines regulator, in what experts say is a “new frontier for the drugs”.
The Therapeutic Goods Administration (TGA) granted approval in December 2024 for semaglutide 2.4 mg, sold under the brand name Wegovy, to be used as a complementary therapy for adults with both cardiovascular disease and high body mass index, to reduce the related risk of heart attack, stroke or death.
Sign up for Guardian Australia’s breaking news email
Continue reading…
Source: https://www.theguardian.com/australia-news/2025/feb/18/weight-loss-drug-wegovy-approved-to-treat-heart-disease-in-overweight-and-obese-australian-patients-tga
